In vitro and in vivo activities of tigecycline-colistin combination therapies against carbapenem-resistant enterobacteriaceae

Jonathan W. Betts; Lynette M. Phee; Michael Hornsey; Neil Woodford; David W. Wareham

doi:10.1128/AAC.02449-14

In vitro and in vivo activities of tigecycline-colistin combination therapies against carbapenem-resistant enterobacteriaceae

Jonathan W. Betts
, Lynette M. Phee
, Michael Hornsey
, Neil Woodford
, David W. Wareham^*

^*Corresponding author for this work

Chief Scientific Officer Group Office

Research output: Contribution to journal › Article › peer-review

53 Citations (Scopus)

Abstract

We assessed the activity of tigecycline (TGC) combined with colistin (COL) against carbapenem-resistant enterobacteria. Synergy occurred in vitro against the majority of isolates, with the exception of Serratia marcescens. In a simple animal model (Galleria mellonella), TGC-COL was superior (P < 0.01) in treating Escherichia coli, Klebsiella pneumoniae, and Enterobacter infections, including those with TGC-COL resistance. Clinical studies are needed to determine whether TGC-COL regimens may be a viable option.

Original language	English
Pages (from-to)	3541-3546
Number of pages	6
Journal	Antimicrobial Agents and Chemotherapy
Volume	58
Issue number	6
DOIs	https://doi.org/10.1128/AAC.02449-14
Publication status	Published - Jun 2014

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Access to Document

10.1128/AAC.02449-14

Cite this

@article{e50e15fca66344e4ba4bae71c430bb7a,

title = "In vitro and in vivo activities of tigecycline-colistin combination therapies against carbapenem-resistant enterobacteriaceae",

abstract = "We assessed the activity of tigecycline (TGC) combined with colistin (COL) against carbapenem-resistant enterobacteria. Synergy occurred in vitro against the majority of isolates, with the exception of Serratia marcescens. In a simple animal model (Galleria mellonella), TGC-COL was superior (P < 0.01) in treating Escherichia coli, Klebsiella pneumoniae, and Enterobacter infections, including those with TGC-COL resistance. Clinical studies are needed to determine whether TGC-COL regimens may be a viable option.",

author = "Betts, \{Jonathan W.\} and Phee, \{Lynette M.\} and Michael Hornsey and Neil Woodford and Wareham, \{David W.\}",

year = "2014",

month = jun,

doi = "10.1128/AAC.02449-14",

language = "English",

volume = "58",

pages = "3541--3546",

journal = "Antimicrobial Agents and Chemotherapy",

issn = "0066-4804",

publisher = "American Society for Microbiology",

number = "6",

}

TY - JOUR

T1 - In vitro and in vivo activities of tigecycline-colistin combination therapies against carbapenem-resistant enterobacteriaceae

AU - Betts, Jonathan W.

AU - Phee, Lynette M.

AU - Hornsey, Michael

AU - Woodford, Neil

AU - Wareham, David W.

PY - 2014/6

Y1 - 2014/6

N2 - We assessed the activity of tigecycline (TGC) combined with colistin (COL) against carbapenem-resistant enterobacteria. Synergy occurred in vitro against the majority of isolates, with the exception of Serratia marcescens. In a simple animal model (Galleria mellonella), TGC-COL was superior (P < 0.01) in treating Escherichia coli, Klebsiella pneumoniae, and Enterobacter infections, including those with TGC-COL resistance. Clinical studies are needed to determine whether TGC-COL regimens may be a viable option.

AB - We assessed the activity of tigecycline (TGC) combined with colistin (COL) against carbapenem-resistant enterobacteria. Synergy occurred in vitro against the majority of isolates, with the exception of Serratia marcescens. In a simple animal model (Galleria mellonella), TGC-COL was superior (P < 0.01) in treating Escherichia coli, Klebsiella pneumoniae, and Enterobacter infections, including those with TGC-COL resistance. Clinical studies are needed to determine whether TGC-COL regimens may be a viable option.

UR - https://www.scopus.com/pages/publications/84901258521

U2 - 10.1128/AAC.02449-14

DO - 10.1128/AAC.02449-14

M3 - Article

C2 - 24687491

AN - SCOPUS:84901258521

SN - 0066-4804

VL - 58

SP - 3541

EP - 3546

JO - Antimicrobial Agents and Chemotherapy

JF - Antimicrobial Agents and Chemotherapy

IS - 6

ER -

In vitro and in vivo activities of tigecycline-colistin combination therapies against carbapenem-resistant enterobacteriaceae

Abstract

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this